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ABSTRACT 
Reducing treatment complexity can be achieved through the use of single-tablet triple fixed-dose combinations of oral hypoglycemic agents. A 
simple, precise and accurate reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the 
simultaneous determination of Metformin (MET), Voglibose (VOG) and Pioglitazone (PIO) in pharmaceutical dosage forms. Chromatographic 
separation was achieved on an Younglin (SK) gradient System with UV 730 D detector and Cosmosil C18 (250 x 4.6 mm, 5μm) column, 
maintained at 45°C using 0.1% v/v acetonitrile: triethylamine (30:70, v/v), pH 2.5 with flow rate 0.8 ml/min with injection volume at 20 μl and 
wavelength ultraviolet detection at 232 nm. MET, PIO and VOG obey Beer–Lambert’s law over the concentration range of 200-600 µg/ml, 30-90 
µg/ml and 0.08-0.24 µg/ml, respectively, with regression equations y=2.021x -186.7 (MET) (R2 = 0.998), y=9.876x-202.31 (PIO) (R2 = 0.999),   
and y= 502.3x-17.23 (VOG) (R2 = 0.999). % RSD and recoveries were 100.57-101.60 for MET, 99.79-102.61 for PIO and 100.02-101.05 for VOG 
indicate good accuracy of method. The marketed formulation analyzed using developed method and mean % amount were found 101.62, 100.38 
and 98.75 for MET, PIO and VOG respectively with % RSD values NMT 2.0%. The developed spectrophotometric method can be employed for 
routine analysis of MET, VOG and PIO in bulk and tablet formulation. The developed RP-HPLC method was sensitive and selective for estimation 
of metformin, voglibose and pioglitazone in combined dosage form. The method was validated as per ICH guidelines. 
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INTRODUCTION 
In diabetic mellitus treatment, combination rationales for the 
most commonly employed FDC products are to provide 
rationale drug regulatory mechanism and enhance drug 
therapeutic effectiveness1. Following the widespread 
acceptance of two drugs fixed drug combinations (FDC) for 
oral antidiabetic drug (OAD); Indian pharmaceutical 
companies have introduced triple FDC of metformin, 
pioglitazone and voglibose, in varying doses2. Metformin 
biguanide hypoglycemic agent used in the treatment of non-
insulin-dependent diabetes mellitus by improving insulin 
sensitivity at the muscle and liver and pioglitazone by 
improving adipose tissue insulin sensitivity by PPAR-ϒ 
agonism. Voglibose is an α-glucosidase inhibitor that acts by 
reducing the postprandial blood glucose by regulating 
glucose absorption. Studies have shown the effectiveness of 
both these combinations of triple OAD. Fixed drug 
combinations has been associated with improved 
compliance and improved glycemic control3. Reducing the 
number of medication diminishes the complexity of the 
regimen, so that superior patient adherence is anticipated 
with combination products. In general, these kinds of 
multicomponent dosage forms are useful for effective 
therapy and augment patient compliance. Method developed 
can be conveniently used for quality control and routine 
determination of drug in pharmaceutical preparation in 
pharmaceutical industry. Metformin, chemically is 3-
(diaminomethylidene)-1, 1-dimethylguanidine (figure1a). 
Metformin improves glycemic control by improving insulin 
sensitivity and decreasing intestinal absorption of glucose4. 
Voglibose is chemically valiolamine derivative (1S, 2S, 3R, 4S, 
5S)-5-(1, 3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl) 
cyclohexane-1, 2, 3, 4-tetrol and inhibitor of α-glucosidase 
with antihyperglycemic activity (fig. 1b). Voglibose inhibits 
α-glucosidase, an enteric enzyme found in the brush border 
of the small intestines that hydrolyzes oligosaccharides and 
disaccharides into glucose and other monosaccharides. This 
prevents the breakdown of larger carbohydrates into glucose 
and decreases the rise in postprandial blood glucose levels5. 
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Figure 1: Chemical structure of (a) Metformin, (b) Voglibose and (c) Pioglitazone 
 
Pioglitazone is 5-[[4-[2-(5-ethylpyridin-2-yl) ethoxy] phenyl] 
methyl]-1, 3-thiazolidine-2, 4-dione and it is selective 
agonists for the nuclear peroxisome proliferator-activated γ-
receptor (PPARγ) which enhances the transcription of 
several insulin responsive genes (figure1c)5. The 
combination is used for the treatment of diabetes mellitus 
and particularly demonstrated significant decrease in 
glucose level in diabetes. The combination of Metformin 
(MET), Voglibose (VOG), and Pioglitazone (PIO) is widely 
available in the market for the treatment of diabetes 
mellitus. Analysis is important in every product but it is vital 
in medicines as it involves life. Analytical methods are 
necessary to assure the identity, strength, quality, purity and 
bioavailability of drug product and stability6. The assurance 
of quality is achieved through analysis of drug product. 
Reverse phase chromatography is usually a method of first 
choice because of convenience, wide applicability and good 
understanding of operating principles. In the reverse- phase 
HPLC; the relative polarities of the stationary and mobile 
phases are opposite to those in normal HPLC i.e. the 
stationary phase is less polar than the mobile phase and 
consequently the solutes are eluted in order of their 
decreasing polarities. These phases are prepared by treating 
surface silanol groups of silica with orthogonochlorosilane 
reagent. So the reverse phase HPLC is highly preferred for 
the pharmaceutical compounds. Literature survey revealed 
that there are a number of analytical techniques, such as RP-
HPLC, HPLC and UV spectrophotometric methods have been 
reported for this combination in individually or in 
combination of listed two drugs. The RP-HPLC methods were 
reported by Lakshmi K et al.,7 Sonia K et al.8 and UV 
spectroscopy were reported by Sujana K et al.9 and Raj N et 
al.10. There are no any analytical methods reported 
previously for the simultaneous estimation of voglibose, 
pioglitazone and metformin in multicomponent in dosage 
form. There is need to develop accurate method for the 
concurrent determination of these drugs in combined dosage 
forms. Therefore, it was aimed to develop a simple, accurate, 
sensitive and reproducible method for triple dose 
combinations voglibose, pioglitazone and metformin in 
combined dosage forms by RP-HPLC. 
MATERIALS AND METHODS 
Chemicals and reagents  
Active pharmaceutical ingredients of Metformin, 
Pioglitazone and Voglibose were received as gift sample 
from Macloids Pharmaceuticals Ltd. Gujarat, India. Triple 
distilled water from Milliq, acetonitrile and methanol of 
HPLC grade were procured from Merck and ortho-
phosphoric acid of AR grade obtained from Fisher scientific. 
The commercial sample containing Voglibose (0.2 mg), 
Metformin (500 mg) and Pioglitazone (7.5 mg) was 
purchased from local market of D-Bose MP275 brand of 
SALUD Care (I) Pvt. Ltd. Khanapur, Roorkee. All the 
chemicals and reagents were used of analytical grade. 
Instrumentation and chromatographic conditions  
Liquid chromatographic separation was achieved using 
Younglin (SK) gradient system with auto injector and UV 730 
D detector with column cosmosil C18 (4.6×250mm, 5μm) 
with Autochro-3000 software and maintained at 45°C. UV-
Visible spectrophotometer with special bandwidth of 2 mm 
and 10 mm and matched quartz was be used for measuring 
absorbance for MET, VOG and PIO solutions. The mobile 
phase consisting mixture of acetonitrile: 0.1% OPA, pH 
adjusted to 2.5 with triethylamine in the ratio 30:70v/v. and 
filtered through 0.45μm membrane filter and diluent used 
was methanol of HPLC grade for common solvent for 
standard and sample preparation. The column was 
maintained at room temperature (25ºC) and the flow rate 
was 0.8ml/min. The preceding to inject the solutions, the 
column is stabilized for 30 minutes with the mobile phase 
flowing through the system. 20μl of sample was injected in 
HPLC at UV-Visible at a detective wavelength of 232nm. 
Under defined experimental conditions; all the peaks were 
well resolved and free from tailing with good resolution.  
Selection of diluent and Preparation Standard and 
Sample  
Solubility studies were done by dissolving drugs in solvents 
like water and methanol. It was observed that Metformin 
(MET) was freely soluble in water and methanol but 
Voglibose (VOG) and Pioglitazone (PIO) were sparingly 
soluble in water forms turbidity and freely soluble in 
methanol therefore methanol was selected as a common 
solvent.  
Accurately weighed and transferred 500 mg of MET, 7.5 mg 
of PIO and 0.2 mg of VOG standards into a 100.0 ml clean dry 
volumetric flask. Then a small amount of diluent was added 
and the flask was sonicated for 30 min and diluted up the 
mark with diluent to obtained final concentrations of MET, 
PIO and VOG were 5000 µg/ml, 75µg/ml and 2 µg/ml, 
respectively. From the above stock solutions, 1 ml was 
pipette out to a 10ml volumetric flask and the final volume 
was made up with diluent to obtain final concentrations of 
500µg/ml MET, 7.5 µg/ml PIO, and 0.2µg/ml VOG. 
Method development and optimization  
For selection of column, a spiked sample of MET was 
prepared with mixture of VOG and PIO, and injected HPLC 
system with different columns. The required system 
suitability criterion was obtained using cosmosil C18 
(4.6×250mm), 5μm column. 
Method Validation  
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The analytical method was validated as per ICH guidelines 
with respect to parameters such as linearity, accuracy, 
precision, and robustness, limit of detection and limit of 
quantification 11, 12. 
Linearity 
Linearity of this method was assessed by linear regression 
analysis, calculated by least square method. A series of 
solutions were prepared from by diluting the stock solutions 
of MET (200-600 μg/ml), PIO (30-90 μg/ml) and VOG (0.08-
0.24 μg/ml), with mobile phase. 20 μl of mixture of these 
solutions was injected into the HPLC system, and the peak 
area of each of the drug was noted from the chromatogram.  
Accuracy  
For the accuracy study, 10 tablets were weighed and 
powdered. The accuracy of the assay method was evaluated 
in triplicate at three concentration levels (80, 100, and 
120%), and the percentage recoveries were calculated. 
Standard addition and recovery experiments were 
conducted to determine the accuracy of the method for the 
quantification of MET, PIO and VOG, respectively; in the drug 
product and the % RSD was calculated. 
System Suitability 
An accurately weighed quantity of MET working standard 
about 500 mg, PIO 7.5 mg and VOG 0.2 mg where transferred 
into 100.0 ml volumetric flask about 100 ml of methanol was 
added to each of volumetric flask and sonicated to dissolve 
the drug the solution was cooled to the room temperature 
and made up to the mark with methanol to obtained the final 
concentrations of 5000 µg/ml MET, 75 µg/ml PIO and 2 
µg/ml VOG. Pipette out 1.0 ml of these solutions into 10.0 ml 
volumetric flask separately and diluted up to the mark with 
mobile phase to obtain 500 µg/ml MET, 7.5 µg/ml PIO and 
0.2 µg/ml VOG. Filtered mobile phase was allowed to 
equilibrate with stationary phase until steady baseline was 
obtained. A 20l standard drugs solution were injected in 
three replicates and the system suitability parameters were 
recorded.  
Precision  
Precision is the measure of how close the data values are to 
each other for a number of measurements under the same 
analytical conditions. Precision of method was evaluated by 
intraday and interday variation studies. Intraday and 
interday variations were determined by analyzing three 
different solutions of MET, PIO and VOG within the same day 
and three different days over a period of week. Intraday 
precision was estimated by analyzing 200μg/ml, 400μg/ml, 
600μg/ml of MET, 30μg/ml, 60μg/ml, 90μg/ml PIO and 
0.08μg/ml, 0.16μg/ml and 0.24μg/ml of VOG for three times 
within the same day. Interday precision was estimated by 
analyzing above mentioned concentrations of three drugs for 
three different days over a period of week and the % RSD 
was calculated. 
Limit of detection and Limit of quantification 
The LOD and LOQ are both are calculated based on mean 
standard deviation and slope of the calibration curve at the 
levels approaching the LOD and LOQ. ICH guidelines describe 
several approaches to determine the detection and 
quantitation limits. The LOD and LOQ are the lowest level 
and lowest concentration of the analyte respectively in a 
sample that would yield signal to noise ratio of 3.3 for LOD 
and 10 for LOQ. These are determined from the standard 
deviation of the peak response and the slope of the 
calibration curve. 
Robustness 
Robustness was tested using so called factor ‘one factor at a 
time’ method. The factors evaluated were mobile phase 
composition, flow rate, wavelength. The robustness was 
evaluated by changing the flow rate by ± 10%, by changing 
the wavelength by ± 1nm and changing concentration of 
mobile phase ± 1%.  
Analysis of commercial formulations  
Twenty tablets of commercial available D-Bose MP 275 each 
containing 500 mg of Metformin 7.5 mg of Pioglitazone and 
0.2 mg of Voglibose were procured from the local medical 
store and powder equivalent to 500 mg of MET, 7.5 mg of 
PIO and 0.2 mg of VOG was accurately weighed and 
transferred to a 100 ml volumetric flask. The contents were 
thoroughly sonicated with diluent and filtered through 0.45 
μm filter. The extracted solution was further diluted with 
mobile phase as per the requirement and 20 μl of each brand 
was injected in three replicates as per chromatographic 
condition into the HPLC system and the peak areas of the 
three drugs were noted from the chromatogram obtained 
and the percentage recovery was calculated from the linear 
regression equation. Amount of drug present in average 
weight of tablet as per the labeled claim was calculated using 
following formula: 
              
   
   
 
   
   
 
 
  
  …………. (1) 
Where, At = Area count for sample solution, As = Area count 
for standard solution, Ds = Dilution factor for standard, Dt = 
Dilution factor for sample, Lc = Label claim and A = Average 
weight. 
Amount of drugs was calculated using formula; 
    
  
  
        ………….. (2) 
Where, Ew = drug estimated in sample weight (mg), Cs = 
concentration of standard (µg/ml), Au= area of unknown, As= 
area of standard and D= dilution factor. 
RESULTS AND DISCUSSION 
Solubility studies revealed that Metformin (MET) was freely 
soluble in water and methanol, but Voglibose (VOG) and 
Pioglitazone (PIO) were sparingly soluble in water forms 
turbidity and freely soluble in methanol. Therefore, 
methanol was selected as a common solvent for proposed 
method. Optimization of mobile phase can be started only 
after a reasonable chromatogram has been obtained.  
 
Figure 2: Overlain Spectra of MET, PIO and VOG 
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A reasonable chromatogram means that more or less 
symmetrical peaks on the chromatogram after the detection 
of all the compounds. By slight change of the mobile phase 
composition, the position of the peaks can be predicted 
within the range of investigated changes. An optimized 
chromatogram was the one in which all the peaks are 
symmetrical and well separated in less run time. The mobile 
phase was selected on the basis of best separation, peak 
purity index, peak symmetry, theoretical plate etc. So, 
numbers of trials were taken for the selection of mobile 
phase. After number of trials, a mixture of Acetonitrile: 0.1% 
OPA (0.1% OPA in 100 ml) (30:70, v/v) pH adjusted to 2.5 
with triethylamine was selected as a mobile phase. The 
working standard solutions of MET, VOG and PIO were 
scanned in the entire UV range of 400-200nm to get 
absorbance spectrum and overlay spectra of MET, VOG and 
PIO are shown in figure 2.  
The common wavelength of absorption was found to be 232 
nm. So the wavelength selected for the determination of 
MET, PIO and VOG was 232 nm. The different mobile phase 
flow rates (0.7, 0.8, 1.0 ml/min) were investigated. The 
optimum flow rate for which the column plate number (N) 
was maximum, with the best resolution between all 
components and with a short run time was selected. A 
typical chromatogram of MET, VOG and PIO sample is shown 
in figure 3. 
 
 
Figure 3: Chromatogram of MET, PIO and VOG using acetonitrile: 0.1% OPA  
 
A simple, precise, accurate, and robust RP-high performance 
liquid chromatographic method was developed and 
validated for the simultaneous determination of MET, VOG 
and PIO in pharmaceutical dosage forms (Tablets). When 
method development and optimization is complete, it is 
necessary to accomplish method validation. For validation of 
analytical method, the guidelines of the international 
conference on the harmonization of technical requirements 
for the registration of pharmaceuticals for human use has 
recommended validation characteristics including system 
suitability, accuracy (% recovery), linearity, precision were 
investigated. Calibration curves were prepared peak area 
ratios and concentrations were subjected to least square 
linear regression analysis to calculate the calibration 
equations and correlation coefficients. Beer–Lambert’s law 
was obeyed over the concentration range 200-600 μg/ml for 
MET, 30-90 μg/ml for PIO and 0.08-0.24 μg/ml for VOG were 
shown in figure 4. The mean regression equations were 
found as R2 = 0.998, y=2.021x -186.7 for MET, R2 =0.999, 
y=9.876x-202.31 for PIO and R2=0.999, y= 502.3x-17.23 for 
VOG where “y” is the peak area ratio of drugs, “a” is the slope, 
“b” is the intercept and “x” is the concentration of the 
measured solution in µg ml-1. The result shows that there is 
an excellent correlation between the peak area ratios and the 
concentrations of drugs in the range tested. Regression 
equation and linearity range is depicted in table 1. Accuracy 
is the closeness of the best result obtained by the method to 
the true value. The concentration recovered should be within 
±2% to the true value. Accuracy of the developed method 
was confirmed by recovery study as per ICH norms at three 
different concentration levels of 80 %, 100 %, and 120 %. 
This is performed on the basis of recovery studies by 
standard addition method. Standard solutions of pure drugs 
(MET, PIO & VOG) were added in different levels i.e. 80%, 
100 %, 120%. The % recovery of the added standard to the 
assay samples was calculated the average % recoveries 
obtained as 100.57-101.60 for MET, 99.79-102.61 for PIO 
and 100.02-101.05 for VOG indicate good accuracy of the 
method.
 
Table 1: Standard Calibration curves of MET, PIO and VOG 
Sr. No. 
Concentration in µg/ml Peak Area 
MET PIO VOG MET PIO VOG 
1 200 30 0.08 224.20±0.62 95.46±0.72 21.97±0.06 
2 300 45 0.12 415.71±0.05 235.80±1.07 43.54±0.37 
3 400 60 0.16 609.81±5.55 394.09±1.87 63.55±0.09 
4 500 75 0.2 845.35±2.75 540.39±1.68 83.93±0.21 
5 600 90 0.24 1015.24±7.76 684.45±5.10 101.27±1.72 
Slope 2.021 9.876 502.3 
 
Intercept 186.72 202.31 17.23 
Correlative 
Coefficient (R2) 
0.998 0.999 0.999 
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Figure 4: Standard calibration curve of MET, VOG and PIO 
The % mean recoveries were found with % RSD less than 2 for MET, PIO and VOG which fully agrees with system suitability. The 
data was given in the table 2 and chromatograms are shown in figure 5(a), (b), and (c). This showed that, the proposed HPLC 
method for the determination of MET, PIO and VOG was found to be sufficiently accurate. 
Table 2: Accuracy results of MET, PIO and VOG by RP-HPLC 
Sample 
Amount of Added 
(µg/ml) 
Amount recovered 
(μg/ml) 
Recovery 
(%) 
% RSD 
Mean % 
recovery 
MET 
160 162.573±0.876 101.6±0.55 0.54 
0.476 200 200.393±0.9603 100.19±0.96 0.48 
240 241.38±1.001 100.57±0.42 0.41 
PIO 
24 24.06±0.807 99.83±0.44 0.82 
1.106 30 30.7833±0.473 102.61±1.58 1.54 
36 35.896±0.345 99.73±0.96 0.96 
VOG 
0.064 0.064±0.001 100.19±1.33 1.32 
1.2 0.08 0.08±0.001 100.02±1.27 1.27 
0.096 0.097±0.001 101.05±1.03 1.01 
 
 
Figure 5(a): Accuracy 80% chromatogram of MET, PIO and VOG 
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Figure 5(b): Accuracy 100% chromatogram of MET, PIO and VOG 
 
Figure 5(c): Accuracy 120% chromatogram of MET, PIO and VOG 
System suitability is a Pharmacopoeial requirement and is used to verify, whether the resolution and reproducibility of the 
chromatographic system are adequate for analysis to be done. The tests were performed by collecting data from three replicate 
Injections of standard solutions. All the parameters of system suitability were observed within the limits for MET (table 3). 
Table 3: System Suitability Test for MET, PIO and VOG 
Sr. No Drug 
Concentration 
(µg/ml) 
Peak area Amount found 
% Amount 
found 
% RSD 
1 MET 200 226.71±0.33 204.55±0.16 102.27±0.083 0.081 
2 PIO 30 96.40±0.75 30.24±0.075 100.79±0.25 0.24 
3 VOG 0.08 22.83±0.11 0.0797±0.00015 99.66±0.215 0.216 
 
The precision of an analytical method is usually expressed as the standard deviation or relative standard deviation (Coefficient 
of variation) of series of measurements. The sample solution was analyzed by injecting three times into the HPLC system as per 
test procedure and record the retention time and peak. Average retention times for MET, PIO and VOG were 2.74, 4.82 and 10.10 
min, respectively. The results were given in table 4.  
Table 4: Precision data for MET, PIO and VOG 
Drug 
Amount Taken 
(µg/ml) 
Intraday [n= 3] Interday [n= 3] 
Amount Found % RSD Amount Found % RSD 
MET 
200 203.21 1.27 202.53 1.56 
400 403.24 1.04 404.37 0.39 
600 596.47 0.3 596.94 0.36 
PIO 
30 30.12 0.05 30.14 1.49 
60 60.7 0.52 60.9 0.45 
90 89.9 0.23 90.04 0.16 
VOG 
0.08 0.078 1.76 0.078 0.71 
0.16 0.161 0.51 0.159 1.94 
0.24 0.238 1.52 0.24 1.38 
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Reproducibility in retention time and peak area is seen in 
both intra and inter day precision studies with a % RSD 
(NMT than 2%) for both retention time and peak area which 
is in agreement with system suitability. Therefore, the 
proposed HPLC method for the determination of MET, PIO 
and VOG in a tablet was found to be sufficiently precise. To 
ensure the insensitivity of the RP-HPLC method to minor 
changes in the experimental conditions it is important to 
demonstrate robustness of the method. Robustness was 
done by minor deliberate changes in chromatographic 
conditions and retention time of MET, PIO and VOG were 
noted. The factors selected were flow rate, mobile phase and 
temperature and the results remained unaffected. 
Ruggedness of method was checked by using different 
instruments. The relative standard deviation of the results 
obtained from different instruments was <2.0%. The results 
were given in table 5. None of the modifications caused a 
significant change in the resolution between the drugs and 
peak area RSD, tailing factor, peak width or theoretical 
plates. The results of assay of test solution were not affected 
by varying the conditions. They fully agree with the results 
obtained under original conditions. The % RSD for (retention 
time, peak area and % amount found) was not more than 2% 
for MET, PIO and VOG. LOD and LOQ were performed on 
samples containing concentration of analyte, based on 
calibration curve method. Standard solution of MET, VOG 
and PIO were injected in six replicates. Average peak area of 
six analyte was plotted against concentration.LOD and LOQ 
were calculated. The LOD and LOQ were found to be 
5.45μg/ml, 0.93μg/ml, 0.0032μg/ml and 16.52μg/ml, 
2.83μg/ml, 0.0097μg/ml for MET, PIO and VOG respectively. 
The observations and results obtained for each of 
parameters like, accuracy, precision, linearity, robustness 
lies well within the acceptance criteria. So the proposed 
method was simple, accurate, linear, precise, robust and 
used for estimation of drugs. 
 
Table 5: Robustness data of MET, PIO and VOG 
Sr. No. Robustness condition 
MET PIO VOG 
Area % RSD Area % RSD Area % RSD 
1 Flow minus (0.7 ml) 448.8±1.51 0.34 158.74±1.79 1.13 39.57±0.76 1.91 
2 Flow Plus (0.9 ml) 365.47±0.99 0.27 173.47±0.88 0.51 35.18±0.66 1.89 
3 Mobile phase minus (29+71) 468.7±1.77 0.38 216.4±1.46 0.68 46.2±0.66 1.44 
4 Mobile phase Plus (31+69) 418.42±1.55 0.37 167.65±2 1.19 44.53±0.54 1.21 
5 Wavelength minus (231 nm) 431.8±2.32 0.54 163.1±1.35 0.83 34.4±0.67 1.95 
6 Wavelength Plus (233 nm) 287.24±1.71 0.6 179.51±0.91 0.51 38.28±0.77 1.99 
 
A new reversed-phase high performance liquid 
chromatography method was developed for assay of MET, 
PIO and VOG in solid dosage form. The validated method was 
applied for the determination of MET, VOG and PIO in 
commercially available D-Bose MP275 tablets. The results of 
assay (n=3) undertaken yielded 101.62 % (% RSD=0.01) of 
MET, 100.38 % (% RSD=0.3) of PIO and 98.75 % (% 
RSD=0.35%) of VOG. The chromatogram representing the 
sample is depicted figure 6 and 7 while the result is given in 
table 6 and 7. All the results found were in good agreement 
with the label content of marketed formulation. 
 
Table 6: Assay of MET, VOG and PIO in tablet formulation 
Sr. 
No. 
Drug 
Conc. 
(µg/ml) 
Area Amount found % Label claim % RSD 
1 MET  500 840.23±1.32 508.12±0.65 101.62±0.13 0.13 
2 PIO 75 541.24±2.31 75.28±0.23 100.38±0.31 0.43 
3 VOG  0.2 82.09±0.5161 0.1975±0.0007 98.75±0.3535 0.62 
 
Table 7: Statistical data for estimation of MET, PIO and VOG in marketed formulation 
Sr. No. 
MET PIO VOG 
Assay (mg) Assay (%) Assay (mg) Assay (%) Assay (mg) Assay (%) 
1 508.58 101.71 75.12 100.16 0.197 98.5 
2 507.66 101.59 75.45 100.6 0.198 99 
Mean 508.12 101.62 75.28 100.38 0.1975 98.75 
SD 0.65 0.12 0.23 0.31 0.0007 0.3535 
% RSD 0.07 0.01 0.3 0.3 0.35 0.35 
 
The proposed method was found to be linear over selected 
concentration range. System suitability parameters indicate 
good resolution for both the peaks >2. The method was 
found to be accurate and precise as indicated by the results 
of recovery studies and precision studies whose percent 
relative standard deviation is not more than 2%. There were 
no marked changes in the chromatograms which confirmed 
the ruggedness of the method. The standard deviation of % 
assay for sample was calculated, for each parameter in 
robustness studies the relative standard deviation was found 
less than 2%. The low percent relative standard deviation (% 
RSD) value confirms the robustness of method. 
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Figure 6: Standard chromatogram of MET, PIO and VOG 
 
Figure 7: Sample chromatogram of MET, PIO and VOG 
The result of analysis of tablets formulation and recovery 
studies obtained by spectrophotometric method was 
statistically validated and high percentage of recovery 
studies suggest that the developed method was free from 
interferences of excipients generally used in tablet 
formulation. The developed method was statically validated 
in terms of accuracy, precision, linearity and reproducibility. 
Hence, above method can be employed in quality control to 
estimate the amount of MET, VOG and PIO in bulk and 
commercial tablets formulation. 
CONCLUSION 
Metformin, Voglibose and Pioglitazone were well resolved 
under optimized chromatographic conditions indicating the 
selective nature of developed RP-HPLC method. The present 
developed RP-HPLC method was simple, specific, precise, 
accurate, and robust, and therefore, it can be applied for the 
routine quantitative and qualitative including 
pharmacokinetic studies as well as for the determination of 
MET, PIO and VOG in pharmaceutical dosage forms.  
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